Last reviewed · How we verify

Perikabiven In Plastic Container (SODIUM GLYCEROPHOSPHATE)

Fresenius Kabi · FDA-approved approved Quality 25/100

Sodium Glycerophosphate, marketed as Perikabiven by Fresenius Kabi, is a phosphate replenishment therapy primarily indicated for hypophosphatemia. Its key strength lies in its patented composition, which is protected until 2028, providing a competitive edge over off-patent alternatives like sodium bicarbonate and sodium chloride. The primary risk is the presence of multiple generic competitors in the same class, such as magnesium sulfate and ammonium chloride, which could erode market share.

At a glance

Generic nameSODIUM GLYCEROPHOSPHATE
SponsorFresenius Kabi
Therapeutic areaMetabolic
PhaseFDA-approved
First approval2014

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: